The future of molecular diagnostics points toward hyper-personalized, decentralized, and ultra-rapid testing paradigms driven by portable handheld biosensors, artificial intelligence-powered genomic interpretation, and multi-omic single-cell analysis. Point-of-care molecular devices will allow clinicians to sequence complete microbial genomes or tumor mutations directly at the bedside within minutes, facilitating instantaneous, customized treatment decisions.